Evaluation of efficacy and safety of Evolocumab 140  mg in genetically characterized He-FH patients. First experience of Genoa lipid clinic

Introduction: Primary objective was to establish how lipid profile is modified in patients affected by Heterozygous Familial Hypercholesterolemia (He-FH) treated with high intensity statin therapy in association to Ezetimibe 10 mg after eight weeks of therapy with Evolocumab, the new antiPCSK9 monoclonal antibody; secondary objective was to verify the tolerability of the product.

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - December 31, 2016 Category: Nutrition Authors: G. Bruzzone, P. Lopena, G. Balleari, P. Dapino, R. Fresa, A. Pende, F. Dallegri, S. Bertolini, L. Pisciotta Source Type: research